BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30637779)

  • 21. Accurate transcriptome assembly by Nanopore RNA sequencing reveals novel functional transcripts in hepatocellular carcinoma.
    Fang Y; Chen G; Chen F; Hu E; Dong X; Li Z; He L; Sun Y; Qiu L; Xu H; Cai Z; Liu X
    Cancer Sci; 2021 Sep; 112(9):3555-3568. PubMed ID: 34255396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of DEK expression by AP-2α and methylation level of DEK promoter in hepatocellular carcinoma.
    Qiao MX; Li C; Zhang AQ; Hou LL; Yang J; Hu HG
    Oncol Rep; 2016 Oct; 36(4):2382-90. PubMed ID: 27499261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skipping of exon 10 in
    Shen L; Lei S; Zhang B; Li S; Huang L; Czachor A; Breitzig M; Gao Y; Huang M; Mo X; Zheng Q; Sun H; Wang F
    Theranostics; 2020; 10(13):5719-5735. PubMed ID: 32483414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of a novel LncRNA AC104958.2 stabilized by PCBP2 promotes proliferation and microvascular invasion in hepatocellular carcinoma.
    Ma Z; Li S; Wang Y; Zhang J; Zeng X
    Exp Cell Res; 2021 Oct; 407(1):112791. PubMed ID: 34418457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-generation sequencing reveals alternative L-DOPA decarboxylase (DDC) splice variants bearing novel exons, in human hepatocellular and lung cancer cells.
    Papatsirou M; Adamopoulos PG; Artemaki PI; Georganti VP; Scorilas A; Vassilacopoulou D; Kontos CK
    Gene; 2021 Feb; 768():145262. PubMed ID: 33141052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma.
    Soto M; Reviejo M; Al-Abdulla R; Romero MR; Macias RIR; Boix L; Bruix J; Serrano MA; Marin JJG
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165687. PubMed ID: 31953214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant splicing of Hugl-1 is associated with hepatocellular carcinoma progression.
    Lu X; Feng X; Man X; Yang G; Tang L; Du D; Zhang F; Yuan H; Huang Q; Zhang Z; Liu Y; Strand D; Chen Z
    Clin Cancer Res; 2009 May; 15(10):3287-96. PubMed ID: 19447873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.
    Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F
    J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma.
    Wang XQ; Luk JM; Leung PP; Wong BW; Stanbridge EJ; Fan ST
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):483-9. PubMed ID: 15701831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and validation of alternative splicing isoforms as novel biomarker candidates in hepatocellular carcinoma.
    Wu P; Zhou D; Wang Y; Lin W; Sun A; Wei H; Fang Y; Cong X; Jiang Y
    Oncol Rep; 2019 Mar; 41(3):1929-1937. PubMed ID: 30592283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein tyrosine phosphatase non-receptor type 12 (PTPN12), negatively regulated by miR-106a-5p, suppresses the progression of hepatocellular carcinoma.
    Liang Z; Li X; Duan F; Song L; Wang Z; Li X; Yang P; Li L
    Hum Cell; 2022 Jan; 35(1):299-309. PubMed ID: 34784010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An alternative POLDIP3 transcript promotes hepatocellular carcinoma progression.
    Liu XN; Yuan JH; Wang TT; Pan W; Sun SH
    Biomed Pharmacother; 2017 May; 89():276-283. PubMed ID: 28236701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HBx mediated Increase of SIRT1 Contributes to HBV-related Hepatocellular Carcinoma Tumorigenesis.
    Wang Q; Cheng ST; Chen J
    Int J Med Sci; 2020; 17(12):1783-1794. PubMed ID: 32714081
    [No Abstract]   [Full Text] [Related]  

  • 34. Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors.
    Jin YJ; Byun S; Han S; Chamberlin J; Kim D; Kim MJ; Lee Y
    BMC Med Genomics; 2019 Dec; 12(Suppl 8):175. PubMed ID: 31856847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms of pathogenesis in hepatocellular carcinoma revealed by RNA‑sequencing.
    Liu Y; Yang Z; Du F; Yang Q; Hou J; Yan X; Geng Y; Zhao Y; Wang H
    Mol Med Rep; 2017 Nov; 16(5):6674-6682. PubMed ID: 28901494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.
    Yea S; Narla G; Zhao X; Garg R; Tal-Kremer S; Hod E; Villanueva A; Loke J; Tarocchi M; Akita K; Shirasawa S; Sasazuki T; Martignetti JA; Llovet JM; Friedman SL
    Gastroenterology; 2008 May; 134(5):1521-31. PubMed ID: 18471523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptome-Wide Analysis Reveals the Landscape of Aberrant Alternative Splicing Events in Liver Cancer.
    Li S; Hu Z; Zhao Y; Huang S; He X
    Hepatology; 2019 Jan; 69(1):359-375. PubMed ID: 30014619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative Splicing in Hepatocellular Carcinoma.
    Lee SE; Alcedo KP; Kim HJ; Snider NT
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):699-712. PubMed ID: 32389640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
    Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y;
    Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma.
    Song H; Sun N; Lin L; Wei S; Zeng K; Liu W; Wang C; Zhong X; Wang M; Wang S; Zhou B; Lv C; Liu W; Zhao Y
    Cancer Sci; 2020 Oct; 111(10):3665-3678. PubMed ID: 32745318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.